tbuckley/cabot-search huggingface dataset:
Reliability of extracellular contrast versus gadoxetic acid in assessing small liver lesions using liver imaging reporting and data system v.2018 and European association for the study of the liver criteria
Authors: Jordi Rimola, Víctor Sapena, Giuseppe Brancatelli, Anna Darnell, Laura Forzenigo, Aline Mähringer‐Kunz, Anita Paisant, Matteo Renzulli, Wolfgang Schima, Sylvain Terraz, Carlos Valls, Mathilde Wagner, Carmen Ayuso, Valerie Vilgrain, Maria Reig, Maxime Ronot
Journal: Hepatology (2022)

The diagnostic accuracy of Liver Imaging Reporting and Data System (LI-RADS) v.2018 and European Association for the Study of the Liver (EASL) criteria for the diagnosis of HCC have been widely evaluated, but their reliability should be investigated. We aimed to assess and compare the reliability of LI-RADS v.2018 and EASL criteria for the diagnosis of HCC using MRI with extracellular contrast agents (ECAs) and gadoxetic acid (GA) and determine the effect of ancillary features on LI-RADS reliability. Ten readers reviewed MRI studies of 92 focal liver lesions measuring <3 cm acquired with ECAs and GA <1 month apart from two prospective trials, assessing EASL criteria, LI-RADS major and ancillary features, and LI-RADS categorization with and without including ancillary features. Inter-reader agreement for definite HCC diagnosis was substantial and similar for the two contrasts for both EASL and LI-RADS criteria. For ECA-MRI and GA-MRI, respectively, inter-reader agreement was k = 0.72 (95% CI, 0.63-0.81) and k = 0.72 (95% CI, 0.63-0.80); for nonrim hyperenhancement, k = 0.63 (95% CI, 0.54-0.72) and k = 0.57 (95% CI, 0.48-0.66); and for nonperipheral washout, k = 0.49 (95% CI, 0.40-0.59) and k = 0.48 (95% CI, 0.37-0.58) for enhancing capsule. The inter-reader agreement for LI-RADS after applying ancillary features remained in the same range of agreement. Agreement for definite HCC was substantial and similar for both scoring systems and the two contrast agents in small focal liver lesions. Agreement for LI-RADS categorization was lower for both contrast agents, and including LI-RADS ancillary features did not improve agreement.
Lack of Concordance in Symptomatic Adverse Event Reporting by Children, Clinicians, and Caregivers: Implications for Cancer Clinical Trials
Authors: David R. Freyer, Li Lin, Jennifer W. Mack, Scott H. Maurer, Molly McFatrich, Justin N. Baker, Shana S. Jacobs, Nicole Lucas, Janice S. Withycombe, Deborah Tomlinson, Katie Rose Villabroza, Mia K. Waldron, Pamela S. Hinds, Bryce B. Reeve
Journal: Journal of Clinical Oncology (2022)

To examine concordance in symptomatic adverse event (AE) grading using the Common Terminology Criteria for Adverse Events (CTCAE 4.0) for clinicians and its patient-reported outcome (PRO) versions for children (Ped-PRO-CTCAE) and caregivers (Ped-PRO-CTCAE [Caregiver]).
Generation of αGal-enhanced bifunctional tumor vaccine
Authors: Jian He, Yu Huo, Zhikun Zhang, Yiqun Luo, Xiuli Liu, Qiaoying Chen, Pan Wu, Wei Shi, Tao Wu, Chao Tang, Huixue Wang, Lan Li, Xiyu Liu, Yong Huang, Yongxiang Zhao, Lu Gan, Bing Wang, Liping Zhong
Journal: Acta Pharmaceutica Sinica B (2022)

Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis and high mortality. In this study, we demonstrated a novel vaccine targeting HCC and tumor neovascular endothelial cells by fusing recombinant MHCC97H cells expressing porcine α-1,3-galactose epitopes (αGal) and endorphin extracellular domains (END) with dendritic cells (DCs) from healthy volunteers. END+/Gal+-MHCC97H/DC fusion cells induced cytotoxic T lymphocytes (CTLs) and secretion of interferon-gamma (IFN-γ). CTLs targeted cells expressing αGal and END and tumor angiogenesis. The fused cell vaccine can effectively inhibit tumor growth and prolong the survival time of human hepatoma mice, indicating the high clinical potential of this new cell based vaccine.
IL-4 polarized human macrophage exosomes control cardiometabolic inflammation and diabetes in obesity
Authors: Tuan Anh Phu, Martin Ng, Ngan K. Vu, Laura Bouchareychas, Robert L. Raffai
Journal: Molecular Therapy (2022)

Cardiometabolic disease is an increasing cause of morbidity and death in society. While M1-like macrophages contribute to metabolic inflammation and insulin resistance, those polarized to an M2-like phenotype exert protective properties. Building on our observations reporting M2-like macrophage exosomes in atherosclerosis control, we tested whether they could serve to control inflammation in the liver and adipose tissue of obese mice. In thinking of clinical translation, we studied human THP-1 macrophages exposed to interleukin (IL)-4 as a source of exosomes (THP1-IL4-exo). Our findings show that THP1-IL4-exo polarized primary macrophages to an anti-inflammatory phenotype and reprogramed their energy metabolism by increasing levels of microRNA-21/99a/146b/378a (miR-21/99a/146b/378a) while reducing miR-33. This increased lipophagy, mitochondrial activity, and oxidative phosphorylation (OXPHOS). THP1-IL4-exo exerted a similar regulation of these miRs in cultured 3T3-L1 adipocytes. This enhanced insulin-dependent glucose uptake through increased peroxisome proliferator activated receptor gamma (PPARγ)-driven expression of GLUT4. It also increased levels of UCP1 and OXPHOS activity, which promoted lipophagy, mitochondrial activity, and beiging of 3T3-L1 adipocytes. Intraperitoneal infusions of THP1-IL4-exo into obese wild-type and Ldlr
Abstract P3-03-21: Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean?
Authors: Kristien Keymeulen, Sandra Geurts, Loes Kooreman, Lucien Duijm, Sanne Engelen, Sigrid Vanwetswinkel, Ernest Luiten, Sabine Siesling, Adri Voogd, Vivianne Tjan-Heijnen
Journal: Cancer Research (2022)

Abstract Background: For patients with ductal carcinoma in situ (DCIS), data about contralateral breast cancers detected by MRI at primary diagnosis and the impact of MRI use on the incidence and stage of contralateral breast cancers during follow-up are scarce. Methods: We selected all women diagnosed with a primary DCIS in the Netherlands in 2011-2015 from the Netherlands Cancer Registry. The synchronous and metachronous detection of contralateral DCIS and contralateral invasive breast cancer was assessed for patients who did receive an MRI upon primary diagnosis (MRI group) and for an age-matched control group without MRI. Incidence of contralateral disease during follow-up was calculated using competing risk methods.Results: Of the 8486 patients diagnosed with primary DCIS, 1571 (19%) received an MRI. In the MRI group, 0.8% of patients were diagnosed with a synchronous contralateral DCIS and 1.3% with synchronous contralateral invasive breast cancer. Median follow-up time was 6.4 years (IQR: 5.1-7.6). The estimated five-year cumulative incidence of synchronous plus metachronous contralateral DCIS was 2.0% (95% CI: 1.4%-2.8%)) for the MRI group and 0.9% (95% CI: 0.5%-1.5%) for the age-matched control group. The five-year cumulative incidence of contralateral invasive breast cancer was 3.5% (95% CI: 2.7%-4.5%) for the MRI group and 2.3% (95% CI: 1.6%-3.1%) for the age-matched control group. In patients aged &amp;lt;50 years, the cumulative incidence of metachronous contralateral DCIS was statistically significantly higher in the MRI group than in the age-matched controls (sHR= 4.22 (95%CI: 1.19-14.99), P=0.03). This was not the case in patients aged 50-74 years (sHR=0.89 (95%CI: 0.41-1.93), P=0.77). Conclusions: MRI led to more frequent detection of synchronous contralateral invasive breast cancers without lowering the number of metachronous contralateral invasive breast cancers. In patients aged below 50 years, MRI added to conventional imaging led to a persisting higher rate of DCIS diagnosed in the opposite breast, also without influencing the occurrence of invasive breast cancers being detected during the first five years of follow-up. Footnotes Citation Format: Kristien Keymeulen, Sandra Geurts, Loes Kooreman, Lucien Duijm, Sanne Engelen, Sigrid Vanwetswinkel, Ernest Luiten, Sabine Siesling, Adri Voogd, Vivianne Tjan-Heijnen. Contralateral breast cancers detected by pre-operative MRI in patients diagnosed with DCIS: Whart do they mean? [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-03-21.
Addressing Food Insecurity and Improving Food Allergy Management among Pediatric Patient/Caregiver Dyads During the COVID Pandemic
Authors: Marleni Albarran, Christopher Warren, Sharon Chinthrajah, Erin Martinez, Lauren Casareno, Alyssa Rodriguez, Emily Brown, Quinlan Hampton, Kristine Martinez, Laurie Kost
Journal: Journal of Allergy and Clinical Immunology (2022)
PREGNANCY OUTCOMES IN PULMONARY HYPERTENSION: IS IT ALWAYS WORSE? NEWER INSIGHTS FROM M-PAC REGISTRY
Authors: Justin Paul Gnanaraj, Anne Princy S, Anju S, Ravindran R, Manohar G, Ravishankar G, Swaminathan N, Meena M, Anitha S, Ramya S, Vijaya S, Shoba S, Kanmani K, Venkatesan S
Journal: Journal of the American College of Cardiology (2022)
Sex-Biased<i>ZRSR2</i>Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
Authors: Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A.G. Booth, Christopher M. Kenyon, Lucia Cabal-Hierro, Justin Taylor, Sunhee S. Kim, Gabriel K. Griffin, Mahmoud Ghandi, Jia Li, Yvonne Y. Li, Fanny Angelot-Delettre, Sabeha Biichle, Michael Seiler, Silvia Buonamici, Scott B. Lovitch, Abner Louissaint, Elizabeth A. Morgan, Fabrice Jardin, Pier Paolo Piccaluga, David M. Weinstock, Peter S. Hammerman, Henry Yang, Marina Konopleva, Naveen Pemmaraju, Francine Garnache-Ottou, Omar Abdel-Wahab, H. Phillip Koeffler, Andrew A. Lane
Journal: Cancer Discovery (2021)

Abstract Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive leukemia of plasmacytoid dendritic cells (pDC). BPDCN occurs at least three times more frequently in men than in women, but the reasons for this sex bias are unknown. Here, studying genomics of primary BPDCN and modeling disease-associated mutations, we link acquired alterations in RNA splicing to abnormal pDC development and inflammatory response through Toll-like receptors. Loss-of-function mutations in ZRSR2, an X chromosome gene encoding a splicing factor, are enriched in BPDCN, and nearly all mutations occur in males. ZRSR2 mutation impairs pDC activation and apoptosis after inflammatory stimuli, associated with intron retention and inability to upregulate the transcription factor IRF7. In vivo, BPDCN-associated mutations promote pDC expansion and signatures of decreased activation. These data support a model in which male-biased mutations in hematopoietic progenitors alter pDC function and confer protection from apoptosis, which may impair immunity and predispose to leukemic transformation. Significance: Sex bias in cancer is well recognized, but the underlying mechanisms are incompletely defined. We connect X chromosome mutations in ZRSR2 to an extremely male-predominant leukemia. Aberrant RNA splicing induced by ZRSR2 mutation impairs dendritic cell inflammatory signaling, interferon production, and apoptosis, revealing a sex- and lineage-related tumor suppressor pathway. This article is highlighted in the In This Issue feature, p. 275
2022 ACC Health Policy Statement on Building Respect, Civility, and Inclusion in the Cardiovascular Workplace
Authors: Pamela S. Douglas, Michael J. Mack, David A. Acosta, Emelia J. Benjamin, Cathleen Biga, Sharonne N. Hayes, Nkechinyere N. Ijioma, Lisa Jay-Fuchs, Akshay K. Khandelwal, John A. McPherson, Jennifer H. Mieres, Robert O. Roswell, Partho P. Sengupta, Natalie Stokes, Enid A. Wade, Clyde W. Yancy
Journal: Journal of the American College of Cardiology (2022)
Abstract P3-09-10: <i>NTRK1/2/3</i> fusions are observed in both secretory and non-secretory breast cancers
Authors: Ethan Sokol, Sophia Maund, Jeffrey Ross, Timothy Wilson
Journal: Cancer Research (2022)

Abstract Background NTRK1/2/3 kinase fusions are rare oncogenic drivers found in &amp;lt;1% of solid tumors. NTRK fusion-positive (NTRK+) solid tumors have shown meaningful clinical response to small molecule NTRK inhibitors such as entrectinib and larotrectinib, and broad genomic testing will help identify patients (pts) with these rare alterations. NTRK fusions occur more frequently in some cancers than others. For example, NTRK fusions are characteristic of secretory breast cancers (BCa), and it has been posited that non-secretory BCa lack druggable NTRK fusions (PMID: 30707464). However, these conclusions were drawn on limited patient populations. Here we show evidence of NTRK fusions in both secretory and non-secretory breast tumors in the largest real-world cohort of NTRK+ breast tumors reported to date. Methods Comprehensive genomic profiling of at least 324 cancer-related genes, including NTRK1/2/3, was done at Foundation Medicine on de-identified all-comer BCa pts during the course of routine clinical care. Pathology reports and hematoxylin and eosin (H&amp;E) images of NTRK+ breast tumor tissue were examined by a board-certified pathologist for designation of secretory vs. non-secretory phenotype. Results NTRK fusions were identified in 23 BCa specimens. H&amp;E images were available for review in 22 cases, and another was confirmed as secretory via the pathology report. Pathologist review of those 23 cases revealed that NTRK fusions were present in 11 with secretory phenotypes, 11 with non-secretory phenotypes, and 1 with a mixed secretory phenotype. Secretory cases most often harbored a ETV6-NTRK3 fusion (n=7) with additional recurrent fusions seen in TPM3-NTRK1 (n=2) and LMNA-NTRK1 (n=2). Non-secretory breast cancers also harbored ETV6-NTRK3 (n=2), TPM3-NTRK1 (n=1), and LMNA-NTRK1 (n=1) fusions, as well as several unique fusion events that retain the NTRK kinase domain. Conclusions While rare, NTRK fusions occur in a wide variety of tumor types. Within BCa, this includes both secretory and non-secretory phenotypes, with half of the identified alterations occurring in non-secretory BCa. Recurrent events, including ETV6-NTRK3, were observed in both populations. These data support NTRK fusion testing for all BCa pts with both secretory and non-secretory histologic subtypes. Citation Format: Ethan Sokol, Sophia Maund, Jeffrey Ross, Timothy Wilson. NTRK1/2/3 fusions are observed in both secretory and non-secretory breast cancers [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P3-09-10.
EOSINOPHILIC MYOCARDITIS AND LOEFFLER ENDOCARDITIS IN THE SETTING OF HYPEREOSINOPHILIC SYNDROME: DEMOGRAPHICS, CARDIAC IMAGING, MANAGEMENT AND OUTCOMES
Authors: Matthew S. Reeder, Saberio Lo Presti Vega, Richard A. Grimm, Brian P. Griffin, Bo Xu
Journal: Journal of the American College of Cardiology (2022)
Longitudinal Trajectories of Multiple Nicotine Product Use Among Youths in the Population Assessment of Tobacco and Health Study
Authors: Patricia Simon, Yannuo Jiang, Eugenia Buta, Carolyn E. Sartor, Suchitra Krishnan-Sarin, Ralitza Gueorguieva
Journal: JAMA Network Open (2022)

Multiple nicotine product use (MNPU) among youths is a significant public health concern. Much remains unknown about the patterns of MNPU in youths, including how socioecological factors influence trajectories of MNPU, which may inform targeted prevention.
LIRAGLUTIDE SUPPRESSES IN VIVO ATHEROSCLEROSIS PROGRESSION AND INFLAMMATION IN RABBITS WITH NORMOGLYCEMIA
Authors: Mohamad Kassab, Haitham Khraishah, Andrew Thrapp, Graham Spicer, Paishiun Nelson Hsieh, Mohammed M. Chowdhury, Aatira Vijay, Yoichiro Kawamura, Adam Mauskapf, Guillermo Tearney, Farouc A. Jaffer
Journal: Journal of the American College of Cardiology (2022)
RUPTURED PRIMARY CARDIAC HYDATID CYST PRESENTING AS CARDIAC TAMPONADE- A GLIMPSE OF ITS DIAGNOSTIC PERPLEXITY AND SUCCESSFUL RECOVERY
Authors: Suhas Raj, Kannan P, Gunasekaran R, Pachaiyappan P, Saravana Babu, Gnanavel P, Suresh Prabhu, Ramkumar V, Dheeraj Jeswani
Journal: Journal of the American College of Cardiology (2022)
ASSESSMENT OF ABNORMAL RIGHT VENTRICULAR VORTICITY IN REPAIRED TETRALOGY OF FALLOT PATIENTS USING DOPPLER VELOCITY RECONSTRUCTION (DOVER)
Authors: Jonathan Nyce, Brett Meyers, Jiacheng Zhang, Lowell Frank, Elias Balaras, Pavlos Vlachos, Yue-Hin Loke
Journal: Journal of the American College of Cardiology (2022)
Health status improvement with ferric carboxymaltose in heart failure with reduced ejection fraction and iron deficiency
Authors: Javed Butler, Muhammad Shahzeb Khan, Tim Friede, Ewa A. Jankowska, Vincent Fabien, Udo‐Michael Goehring, Fabio Dorigotti, Marco Metra, Ileana L. Piña, Andrew J.S. Coats, Giuseppe Rosano, Josep Comin‐Colet, Dirk J. Van Veldhuisen, Gerasimos S. Filippatos, Stefan D. Anker, Piotr Ponikowski
Journal: European Journal of Heart Failure (2022)

Intravenous ferric carboxymaltose (FCM) has been shown to improve overall quality of life in iron-deficient heart failure with reduced ejection fraction (HFrEF) patients at a trial population level. This FAIR-HF and CONFIRM-HF pooled analysis explored the likelihood of individual improvement or deterioration in Kansas City Cardiomyopathy Questionnaire (KCCQ) domains with FCM versus placebo and evaluated the stability of this response over time.Changes versus baseline in KCCQ overall summary score (OSS), clinical summary score (CSS) and total symptom score (TSS) were assessed at weeks 12 and 24 in FCM and placebo groups. Mean between-group differences were estimated and individual responder analyses and analyses of response stability were performed. Overall, 760 (FCM, n = 454) patients were studied. At week 12, the mean improvement in KCCQ OSS was 10.6 points with FCM versus 4.8 points with placebo (least-square mean difference [95% confidence interval, CI] 4.36 [2.14; 6.59] points). A higher proportion of patients on FCM versus placebo experienced a KCCQ OSS improvement of ≥5 (58.3% vs. 43.5%; odds ratio [95% CI] 1.81 [1.30; 2.51]), ≥10 (42.4% vs. 29.3%; 1.73 [1.23; 2.43]) or ≥15 (32.1% vs. 22.6%; 1.46 [1.02; 2.11]) points. Differences were similar at week 24 and for CSS and TSS domains. Of FCM patients with a ≥5-, ≥10- or ≥15-point improvement in KCCQ OSS at week 12, >75% sustained this improvement at week 24.Treatment of iron-deficient HFrEF patients with intravenous FCM conveyed clinically relevant improvements in health status at an individual-patient level; benefits were sustained over time in most patients.
Nitrogen-based Bisphosphonate Use and Ovarian Cancer Risk in Women Aged 50 Years and Older
Authors: Karen M Tuesley, Penelope M Webb, Melinda M Protani, Katrina Spilsbury, Sallie-Anne Pearson, Michael D Coory, Peter Donovan, Christopher Steer, Louise M Stewart, Nirmala Pandeya, Susan J Jordan
Journal: JNCI Journal of the National Cancer Institute (2022)

There are few readily modifiable risk factors for epithelial ovarian cancer; preclinical studies suggest bisphosphonates could have chemopreventive actions. Our study aimed to assess the association between use of nitrogen-based bisphosphonate medicine and risk of epithelial ovarian cancer, overall and by histotype.We conducted a case-control study nested within a large, linked administrative dataset including all Australian women enrolled for Medicare, Australia's universal health insurance scheme, between July 2002 and December 2013. We included all women with epithelial ovarian cancer diagnosed at age 50 years and older between July 1, 2004, and December 31, 2013 (n = 9367) and randomly selected up to 5 controls per case, individually matched to cases by age, state of residence, area-level socioeconomic status, and remoteness of residence category (n = 46 830). We used prescription records to ascertain use of nitrogen-based bisphosphonates (ever use and duration of use), raloxifene, and other osteoporosis medicines (no nitrogen-based bisphosphonates, strontium and denosumab). We calculated adjusted odds ratios (OR) and 95% confidence intervals (CI) using conditional logistic regression.Ever use of nitrogen-based bisphosphonates was associated with a reduced risk of epithelial ovarian cancer compared with no use (OR = 0.81, 95% CI = 0.75 to 0.88). There was a reduced risk of endometrioid (OR = 0.51, 95% CI = 0.33 to 0.79) and serous histotypes (OR = 0.84, 95% CI = 0.75 to 0.93) but no association with the mucinous or clear cell histotypes.Use of nitrogen-based bisphosphonates was associated with a reduced risk of endometrioid and serous ovarian cancer. This suggests the potential for use for prevention, although validation of our findings is required.
SAFETY AND EFFECTIVENESS OF THERMOCOOL ST CATHETER FOR ABLATION OF PERSISTENT ATRIAL FIBRILLATION USING REAL-WORLD DATA
Authors: Sanket Shishir Dhruva, Shumin Zhang, Jiajing Chen, Peter Noseworthy, Amit A. Doshi, Kolade Agboola, Jeph Herrin, Guoqian Jiang, Yue Yu, Guy Cafri, Kimberly Collison Farr, Keondae Ervin, Joseph S. Ross, Paul Coplan, Joseph P. Drozda
Journal: Journal of the American College of Cardiology (2022)
The FoxOs are in the ApoM house
Authors: MacRae F. Linton, Patricia G. Yancey, Zoe M. Leuthner, Jonathan D. Brown
Journal: Journal of Clinical Investigation (2022)

The prevalence of metabolic syndrome continues to increase globally and heightens the risk for cardiovascular disease (CVD). Insulin resistance is a core pathophysiologic mechanism that causes abnormal carbohydrate metabolism and atherogenic changes in circulating lipoprotein quantity and function. In particular, dysfunctional HDL is postulated to contribute to CVD risk in part via loss of HDL-associated sphingosine-1-phosphate (S1P). In this issue of the JCI, Izquierdo et al. demonstrate that HDL from humans with insulin resistance contained lower levels of S1P. Apolipoprotein M (ApoM), a protein constituent of HDL that binds S1P and controls bioavailability was decreased in insulin-resistant db/db mice. Gain- and loss-of-function mouse models implicated the forkhead box O transcription factors (FoxO1,3,4) in the regulation of both ApoM and HDL-associated S1P. These data have important implications for potential FoxO-based therapies designed to treat lipid and carbohydrate abnormalities associated with human metabolic disease and CVD.
False-Positive Results of Mammography Screening in the Era of Digital Breast Tomosynthesis
Authors: Lydia E. Pace
Journal: JAMA Network Open (2022)

Thao-Quyen H. Ho, MD, PhD; Michael C. S. Bissell, PhD; Karla Kerlikowske, MD; Rebecca A. Hubbard, PhD; Brian L. Sprague, PhD; Christoph I. Lee, MD, MS; Jeffrey A. Tice, MD; Anna N. A. Tosteson, ScD; Diana L. Miglioretti, PhD
TEMPORAL TRENDS AND OUTCOMES OF TRANSCATHETER VERSUS SURGICAL AORTIC VALVE REPLACEMENTIN PATIENTS WITHTRANSTHYRETINCARDIAC AMYLOIDOSIS AND SEVERE AORTIC STENOSIS
Authors: Rahul Gupta, Theresa Maitz, Aaqib Malik, Apurva Vijay Vyas, Nainesh C. Patel, Sabahat Bokhari
Journal: Journal of the American College of Cardiology (2022)
LONG-TERM OUTCOMES OF VETERANS WITH A DIAGNOSIS OF HEART FAILURE AFTER CORONAVIRUS-2019 (COVID-19) INFECTION
Authors: Vishal Khetpal, Julia Berkowitz, Lan Jiang, Shilpa Vijayakumar, Khansa Ahmad, Justin Echouffo Tcheugui, Anupama Menon, Daithi S. Heffernan, Gaurav Choudhary, James Rudolph, Wen-Chih Wu, Sebhat Erqou
Journal: Journal of the American College of Cardiology (2022)
SEX-SPECIFIC ASSOCIATION OF OBSTRUCTIVE SLEEP APNEA WITH CARDIOVASCULAR EVENTS IN PATIENTS WITH ACUTE CORONARY SYNDROME
Authors: Xiao Wang, Jingyao Fan, Ruifeng Guo, Wen Hao, Wei Gong, Yan Yan, Wen Zheng, Hui Ai, Bin Que, Changsheng Ma, Xinliang Ma, Virend K. Somers, Shaoping Nie
Journal: Journal of the American College of Cardiology (2022)